SCHEMBL6975246

SCHEMBL6975246

CC(C)(C)OC(=O)N1CCC(NC(=O)[C@@H]2CCCCN2c2nc3ccccc3o2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
HTT P42858 2/20 0.54
TSHR P16473 1/20 0.54
MAPT P10636 1/20 0.54
EPHX2 P34913 2/20 0.45
EPHX1 P07099 1/20 0.45
USP30 Q70CQ3 1/20 0.42
ALDH1A1 P00352 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PTGES O14684 3/20 0.41
PTGS2 P35354 1/20 0.41
HDAC4 P56524 1/20 0.41
FPR3 P25089 1/20 0.41
FPR2 P25090 1/20 0.41
PARP1 P09874 1/20 0.41
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40
STS P08842 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27495903 0.87 LMNA (0.52) LMNASMN1; SMN2HTTTSHRMAPT
SCHEMBL7680423 0.86 LMNA (0.58) LMNASMN1; SMN2HTTTSHRMAPT
Tert-Butyl Formate SCHEMBL27495904 0.82 LMNA (0.49) LMNASMN1; SMN2HTTTSHRMAPT
SCHEMBL6979378 0.81 LMNA (0.59) LMNASMN1; SMN2HTTTSHRMAPT
SCHEMBL7846258 0.81 LMNA (0.59) LMNASMN1; SMN2HTTTSHRMAPT
SCHEMBL7662748 0.81 ALDH1A1 (0.50) LMNASMN1; SMN2HTTTSHRMAPT
SCHEMBL6971418 0.79 LMNA (0.54) LMNASMN1; SMN2HTTTSHRMAPT
SCHEMBL6974109 0.79 LMNA (0.53) LMNASMN1; SMN2HTTTSHRMAPT
SCHEMBL6976210 0.78 LMNA (0.54) LMNASMN1; SMN2HTTTSHRMAPT
SCHEMBL6970992 0.78 LMNA (0.54) LMNASMN1; SMN2HTTTSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562964-B1 Inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases or other disorders PFIZER INC 2003-05-13 US disclosed
EP-1100797-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER LTD (GB) 2003-02-26 EP disclosed
US-6372736-B1 ENZYME INHIBITORS PFIZER INC 2002-04-16 US disclosed
EP-1100797-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES Pfizer Limited (GB) 2001-05-23 EP disclosed
WO-2000005232-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER LIMITED (GB) 2000-02-03 WO disclosed